Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 10/20 | 0.49 |
| ▸ | CDK4 | P11802 | 8/20 | 0.46 |
| ▸ | CCND1 | P24385 | 8/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.46 |
| ▸ | CDK2 | P24941 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5600331 | 0.91 | CDK4 (0.53) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL5600433 | 0.89 | CRHR1 (0.57) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL5599902 | 0.86 | CDK4 (0.52) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL5599666 | 0.85 | CDK4 (0.54) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL5611027 | 0.83 | CDK4 (0.55) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL7044978 | 0.83 | CDK4 (0.55) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| Acetic Acid SCHEMBL7953282 | 0.82 | CDK4 (0.50) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL7953286 | 0.81 | CDK4 (0.46) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL5599534 | 0.81 | CDK4 (0.53) | CRHR1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL6465742 | 0.80 | CDK4 (0.52) | CRHR1CDK4CCND1CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007522200-A | — | — | 2007-08-09 | — | — | JP | claimed |
| EP-1718311-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | PFIZER INC | 2005-09-22 | — | — | US | claimed |
| WO-2005079807-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | PFIZER INC | 2004-04-29 | — | — | US | claimed |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | claimed |
| EP-0691128-B1 | Use of CRF antagonists | PFIZER (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | PFIZER INC. | 2002-10-24 | — | — | US | claimed |
| US-6387894-B1 | MIXTURE OF CORTICOTROPIN RELEASING FACTOR ANTAGINIST AND RENIN-ANGIOTENSIN SYSTEM INHIBITOR; THERAPY FOR CONGESTIVE HEART FAILURE, HYPOTENSIVE AGENTS | PFIZER INC. | 2002-05-14 | — | — | US | claimed |
| US-6384039-B1 | ADMINISTERING CORTICOTROPIN RELEASING FACTOR ANTAGONIST | PFIZER INC. | 2002-05-07 | — | — | US | claimed |
| US-6200979-B1 | ADMINISTERING SUBSTITUTED PYRAZOLES AND PYZAZOLOPYRIMIDINES FOR TREATING PHOBIAS OBSESSIVE-COMPULSIVE DISORDER, POST-TRAUMATIC STRESS DISORDER, SINGLE EPISODE DEPRESSION, RECURRENT DEPRESSION, DYSTHYMIA, BIPOLAR DISORDERS | BRIGHT GENE M (US) | 2001-03-13 | — | — | US | claimed |
| EP-1059100-A2 | Combinations of CRF antagonists and renin-angiotensin system inhibitors | Pfizer Products Inc. (US) | 2000-12-13 | — | — | EP | claimed |
| EP-1040831-A2 | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death | Pfizer Products Inc. (US) | 2000-10-04 | — | — | EP | claimed |
| EP-0674642-B1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER (US) | 2000-08-23 | — | — | EP | claimed |
| US-6051578-A | Pyrazolopyrimidines for treatment of CNS disorders | PFIZER INC. (US) | 2000-04-18 | — | — | US | claimed |
| EP-0773023-A1 | New uses for corticotropin releasing factor (CRF) antagonists | PFIZER INC. (US) | 1997-05-14 | — | — | EP | claimed |
| EP-0729758-A2 | Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders | PFIZER INC. (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0691128-A1 | Methods of administering CRF antagonists | PFIZER INC. (US) | 1996-01-10 | — | — | EP | claimed |
| EP-0674642-A1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1995-10-04 | — | — | EP | claimed |
| WO-1994013677-A1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | CRH, MC2R, CRHR2 | CRHR1 5/4885CDK4 3208/4885CCND1 3972/4885 |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885CDK4 254/4885CCND1 211/4885 |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885CDK4 4323/4885CCND1 4856/4885 |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885CDK4 254/4885CCND1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.